Active	Status	Sponsor type	Region	Phase	Filter
13 Active 6 Inactive 19 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

6 Trials

Active Trials   Industry lead sponsorIndustry collaborator

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Zhang, Fan
ESPTTN, NCT06423235: Efficacy and Safety of Prunella Oral Liquid in the Treatment of Thyroid Nodules	Not yet recruiting	4	426	RoW	regular dose of JiRui® Prunella oral liquid, 2x regular dose of JiRui® Prunella oral liquid, regular dose of placebo, 2x regular dose of placebo	Xintian Pharmaceutical	Thyroid Nodule	07/25	07/28
NCT05812014: Clinical Trail of SARS-CoV-2 Bivalent mRNA Vaccine (LVRNA021) in Participants Aged 18 Years and Older	Recruiting	3	9800	RoW	SARS-CoV-2 Bivalent mRNA vaccine (LVRNA021), 0.9% sodium chloride solution	AIM Vaccine Co., Ltd., LiveRNA Therapeutics Inc., Ningbo Rongan Biological Pharmaceutical Co. Ltd.	SARS-CoV-2	03/24	06/24
NCT05939648: A Phase II Clinical Trial to Evaluate the Immunogenicity and Safety of SARS-CoV-2 Bivalent mRNA Vaccine (LVRNA021)	Active, not recruiting	2	450	RoW	SARS-CoV-2 Bivalent mRNA Vaccine, LVRNA021, Saline	AIM Vaccine Co., Ltd., Ningbo Rongan Biological Pharmaceutical Co., Ltd.	SARS-CoV-2	11/23	12/24
PALIZADE, NCT05781750: A Study of Zetomipzomib (KZR-616) in Patients With Active Lupus Nephritis	Suspended	2	279	Europe, US, RoW	zetomipzomib, KZR-616, placebo, matching placebo	Kezar Life Sciences, Inc.	Lupus Nephritis	05/26	07/26
NCT05939596: A Phase I Clinical Trial to Evaluate the Safety, Tolerability, and Immunogenicity of SARS-CoV-2 Bivalent mRNA Vaccine (LVRNA021)	Active, not recruiting	1	60	RoW	SARS-CoV-2 Bivalent mRNA Vaccine, LVRNA021, Saline	AIM Vaccine Co., Ltd., First Affiliated Hospital Bengbu Medical College	SARS-CoV-2	09/23	08/24
Maid, Pablo Jorge
PALIZADE, NCT05781750: A Study of Zetomipzomib (KZR-616) in Patients With Active Lupus Nephritis	Suspended	2	279	Europe, US, RoW	zetomipzomib, KZR-616, placebo, matching placebo	Kezar Life Sciences, Inc.	Lupus Nephritis	05/26	07/26